{"id":50071,"date":"2022-10-26T02:01:41","date_gmt":"2022-10-26T00:01:41","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/bristol-myers-squibb-reports-third-quarter-financial-results-for-2022\/"},"modified":"2022-10-26T02:01:41","modified_gmt":"2022-10-26T00:01:41","slug":"bristol-myers-squibb-reports-third-quarter-financial-results-for-2022","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/bristol-myers-squibb-reports-third-quarter-financial-results-for-2022\/","title":{"rendered":"Bristol Myers Squibb Reports Third Quarter Financial Results for 2022\u00a0"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\n<b>Reports Third Quarter Revenues of $11.2 Billion<\/b>\n<\/li>\n<li>\n<b>Delivers Strong Revenue Growth of 8% from In-Line Products and New Product Portfolio; or 13% When Adjusted for Foreign Exchange<\/b>\n<\/li>\n<li>\n<b>Posts Third Quarter Earnings Per Share of $0.75 and Non-GAAP EPS of $1.99; Includes Net Increase of $0.02 Per Share for GAAP and Non-GAAP EPS Due to Acquired IPRD<sup>1<\/sup> Charges and Licensing Income<\/b>\n<\/li>\n<li>\n<b>Bolsters New Product Portfolio with FDA Approval for <i>Sotyktu<\/i><sup>TM<\/sup>, a First-in-Class TYK2 inhibitor for Adults with Moderate-to-Severe Plaque Psoriasis<\/b>\n<\/li>\n<li>\n<b>Continues to Progress Product Pipeline with Significant Regulatory and Clinical Milestones<\/b>\n<\/li>\n<li>\n<b>Completes Acquisition of Turning Point Therapeutics, Expanding Precision Oncology Portfolio<\/b>\n<\/li>\n<li>\n<b>Adjusts 2022 GAAP EPS Guidance; Reaffirms Non-GAAP EPS Guidance<\/b>\n<\/li>\n<\/ul>\n<p>NEW YORK&#8211;(BUSINESS WIRE)&#8211;<a href=\"https:\/\/twitter.com\/search?q=%24BMY&amp;src=ctag\" target=\"_blank\" rel=\"noopener\">$BMY<\/a> <a href=\"https:\/\/twitter.com\/hashtag\/BMS?src=hash\" target=\"_blank\" rel=\"noopener\">#BMS<\/a>&#8212;<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bms.com%2F&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=Bristol+Myers+Squibb&amp;index=1&amp;md5=235311409db21584d369c04b50e96794\" rel=\"nofollow noopener\" shape=\"rect\">Bristol Myers Squibb<\/a> (NYSE:BMY) today reports results for the third quarter of 2022, which reflect strong in-line and new product portfolio growth.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20221026005143\/en\/785876\/5\/BMS_LOGO.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20221026005143\/en\/785876\/21\/BMS_LOGO.jpg\"><\/a><\/p>\n<p>\n\u201c<!-- no quote -->Our strong results reflect growth of our in-line and new product portfolios,\u201d said <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.bms.com%2Fabout-us%2Fleadership%2Fleadership-team.html&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=Giovanni+Caforio%2C+M.D.&amp;index=2&amp;md5=f512ed02dcfdf909c0e4e2d32adc9171\" rel=\"nofollow noopener\" shape=\"rect\">Giovanni Caforio, M.D.<\/a>, board chair and chief executive officer, Bristol Myers Squibb. \u201c<!-- no quote -->Our teams continue to progress our pipeline and achieve significant regulatory and clinical milestones, including the approval of <i>Sotyktu<\/i>, a first-in-class, TYK2 inhibitor, to treat moderate to severe plaque psoriasis. Our nine new product launches over the last three years including three first-in-class launches this year, combined with progress in our robust and diverse product pipeline, have built a strong foundation for our company. Combined with our financial strength and talented employees, Bristol Myers Squibb is well positioned for growth and to advance new medicines for patients.\u201d\n<\/p>\n<p>\n<sup>1<\/sup>Acquired IPRD refers to certain in-process research and development (\u201cAcquired IPRD\u201d) charges resulting from upfront or contingent milestone payments in connection with asset acquisitions or licensing of third-party intellectual property rights.\n<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwtopsingle bwsinglebottom bwrowaltcolor0 bwpadl0\" colspan=\"11\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>Third Quarter<\/b>\n<\/p>\n<\/td>\n<td class=\"bwtopsingle bwsinglebottom bwrowaltcolor0 bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\"><\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n$ amounts in millions, except per share amounts\n<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"3\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"4\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td colspan=\"1\" rowspan=\"1\"><\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignt bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<b><span class=\"bwuline\">2022<\/span><\/b>\n<\/p>\n<\/td>\n<td class=\"bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignt bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<b><span class=\"bwuline\">2021<\/span><\/b>\n<\/p>\n<\/td>\n<td class=\"bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwpadl0 bwalignc\" colspan=\"3\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<b><span class=\"bwuline\">Change<\/span><\/b>\n<\/p>\n<\/td>\n<td class=\"bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwpadl0 bwalignc\" colspan=\"2\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<b><span class=\"bwuline\">Change<br \/>\n<br \/>Excl. F\/X<\/span><\/b>\n<\/p>\n<\/td>\n<td class=\"bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\nTotal Revenues\n<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n$11,218\n<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n$11,624\n<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb\" colspan=\"2\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(3)%\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb\" colspan=\"4\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n0%\n<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\"><\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\nEarnings Per Share \u2013 GAAP*\n<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n0.75\n<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n0.69\n<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb\" colspan=\"2\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n9%\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb\" colspan=\"4\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\nN\/A\n<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\"><\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\nEarnings Per Share \u2013 Non-GAAP*\n<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n1.99\n<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n1.93\n<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb\" colspan=\"2\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n3%\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb\" colspan=\"4\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\nN\/A\n<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\"><\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p>\n* GAAP and non-GAAP earnings per share include the net impact of Acquired IPRD charges and licensing income which increased by $0.02 per share in the third quarter of 2022 compared to a reduction of ($0.09) per share in the third quarter of 2021.\n<\/p>\n<p>\n<b><span class=\"bwuline\">THIRD QUARTER FINANCIAL RESULTS<\/span><\/b>\n<\/p>\n<p>\n<b>All comparisons are made versus the same period in 2021 unless otherwise stated.<\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nBristol Myers Squibb posted third quarter revenues of $11.2 billion, a decrease of 3%, driven by recent LOE products (primarily <i>Revlimid<\/i>) and foreign exchange impacts, partially offset by in-line products (primarily <i>Eliquis<\/i> and <i>Opdivo<\/i>) and our new product portfolio (primarily <i>Opdualag, Abecma <\/i>and <i>Reblozyl<\/i>). When adjusted for foreign exchange impacts, third quarter revenues remained consistent. Our in-line and new product portfolio increased 8% to $8.6 billion, or 13% when adjusted for foreign exchange impacts.\n<\/li>\n<li>\nU.S. revenues increased 9% to $7.9 billion in the quarter. International revenues decreased 24% to $3.3 billion in the quarter. When adjusted for foreign exchange impacts, international revenues decreased 14%, primarily due to lower demand of <i>Revlimid <\/i>as a result of generic erosion, partially offset by in-line products (primarily <i>Opdivo<\/i>) and our new product portfolio.\n<\/li>\n<li>\nGross margin decreased from 80.3% to 79.0% and on a non-GAAP basis, decreased from 81.1% to 79.8% in the quarter primarily due to product mix, partially offset by foreign exchange impacts and related hedging settlements.\n<\/li>\n<li>\nMarketing, selling and administrative expenses increased 8% to $1.9 billion in the quarter, primarily due to higher costs to support new product launches and cash settlement of Turning Point Therapeutics, Inc. (\u201cTurning Point\u201d) unvested stock awards, partially offset by foreign exchange impacts. On a non-GAAP basis, marketing, selling and administrative expenses increased 4% to $1.9 billion primarily due to higher investments to support new product launches, partially offset by foreign exchange impacts.\n<\/li>\n<li>\nResearch and development expenses decreased 19% to $2.4 billion in the quarter, primarily due to an in-process research and development (IPRD) impairment charge in 2021, timing of clinical development spend and foreign exchange impacts, partially offset by cash settlement of Turning Point unvested stock awards. On a non-GAAP basis, research and development expenses decreased 5% to $2.3 billion in the quarter primarily due to timing of clinical development spend and foreign exchange impacts.\n<\/li>\n<li>\nAcquired IPRD decreased from $271 million in the same period a year ago to $30 million in the current quarter. Acquired IPRD in the current quarter is related to the GentiBio licensing transaction. Acquired IPRD in the same period a year ago was primarily related to the Agenus licensing transaction ($200 million).\n<\/li>\n<li>\nAmortization of acquired intangible assets decreased 5% to $2.4 billion in the quarter, primarily due to a change in the expected expiration of the market exclusivity period for <i>Pomalyst <\/i>to the first quarter of 2026.\n<\/li>\n<li>\nThe GAAP effective tax rate changed from 28.0% to 27.2% in the quarter and non-GAAP effective tax rate changed from 14.6% to 16.9% in the quarter due to changes in previously estimated annual effective tax rates due to jurisdictional earnings mix.\n<\/li>\n<li>\nThe company reported net earnings attributable to Bristol Myers Squibb of $1.6 billion, or $0.75 per share, in the third quarter, compared to $1.5 billion, or $0.69 per share, for the same period a year ago. In addition to the items discussed above, the results include the impact of fair value adjustments on equity investments in both periods.\n<\/li>\n<li>\nThe company reported non-GAAP net earnings attributable to Bristol Myers Squibb of $4.3 billion, or $1.99 per share, in the third quarter, compared to non-GAAP net earnings of $4.3 billion, or $1.93 per share, for the same period a year ago.\n<\/li>\n<li>\nIn addition to the items discussed above, the earnings per share results in the current period include the impact of lower weighted-average common shares outstanding.\n<\/li>\n<\/ul>\n<p>\nBeginning with the first quarter of 2022, significant R&amp;D charges or other income resulting from upfront or contingent milestone payments in connection with asset acquisitions or licensing of third-party intellectual property rights are no longer excluded from non-GAAP results. These R&amp;D charges that were previously specified are now presented in a new financial statement line item labeled Acquired IPRD. GAAP and non-GAAP earnings per share include the net impact of Acquired IPRD charges and licensing income which increased by $0.02 per share in the third quarter of 2022 compared to a reduction of ($0.09) per share in the third quarter of 2021. For purposes of comparability, the non-GAAP financial results for the third quarter of 2021 have been updated to reflect this change. A discussion of the non-GAAP financial measures is included under the \u201cUse of Non-GAAP Financial Information\u201d section.\n<\/p>\n<p>\n<b><span class=\"bwuline\">THIRD QUARTER PRODUCT REVENUE HIGHLIGHTS<\/span><\/b>\n<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwwidth80 bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor0 bwpadl0 bwalignl\" colspan=\"4\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<b>$ amounts in millions<\/b>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwtopsingle bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>Product<\/b>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<b>Quarter Ended<br \/>\n<br \/><\/b><b>September 30, 2022<\/b>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<b>Quarter Ended<br \/>\n<br \/><\/b><b>September 30, 2021<\/b>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<b>% Change from<br \/>\n<br \/>Quarter Ended<br \/>\n<br \/>September 30, 2021<\/b>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<b>% Change from<br \/>\n<br \/>Quarter Ended<br \/>\n<br \/>September 30, 2021<br \/>\n<br \/><\/b><b>(Excl. F\/X Impact)<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth80 bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor0 bwpadl0 bwalignl\" colspan=\"4\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<b>In-Line Products<\/b>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.eliquis.com%2F&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=Eliquis&amp;index=3&amp;md5=7096e9bab4842043cdf912ae625151a8\" rel=\"nofollow noopener\" shape=\"rect\"><i>Eliquis<\/i><\/a>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$2,655\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$2,413\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n10%\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n16%\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.opdivo.com%2F&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=Opdivo&amp;index=4&amp;md5=71f132a02d14f0246626df449f63774c\" rel=\"nofollow noopener\" shape=\"rect\"><i>Opdivo<\/i><\/a>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$2,047\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$1,905\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n7%\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n13%\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.pomalyst.com&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=Pomalyst%2FImnovid&amp;index=5&amp;md5=2ba09d2eccdfedb9b19d2e7b49f7f3b8\" rel=\"nofollow noopener\" shape=\"rect\"><i>Pomalyst<\/i><i>\/Imnovid<\/i><\/a>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$886\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$851\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n4%\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n8%\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.orencia.com%2F&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=Orencia&amp;index=6&amp;md5=10ff11d31f32f42dc4bd0ccd2be8e2cc\" rel=\"nofollow noopener\" shape=\"rect\"><i>Orencia<\/i><\/a>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$883\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$870\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n1%\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n5%\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sprycel.com%2F&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=Sprycel&amp;index=7&amp;md5=a3f2e2fdba10d1676aab3b9135574454\" rel=\"nofollow noopener\" shape=\"rect\"><i>Sprycel<\/i><\/a>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$560\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$551\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n2%\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n7%\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.yervoy.com%2F&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=Yervoy&amp;index=8&amp;md5=c9ac78f6e75b06e4a455813748596857\" rel=\"nofollow noopener\" shape=\"rect\"><i>Yervoy<\/i><\/a>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$523\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$515\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n2%\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n7%\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.empliciti.com&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=Empliciti&amp;index=9&amp;md5=24007d249289b850758f4639c454f07b\" rel=\"nofollow noopener\" shape=\"rect\"><i>Empliciti<\/i><\/a>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$73\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$82\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n(11)%\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n(5)%\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<i>Mature and Other Products**<\/i>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$441\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$480\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n(8)%\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n(4)%\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Total In-Line Products Revenue<\/b>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<b>$8,068<\/b>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<b>$7,667<\/b>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<b>5%<\/b>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<b>10%<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth80 bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor0 bwpadl0 bwalignl\" colspan=\"4\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<b>New Product Portfolio<\/b>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.reblozyl.com%2F&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=Reblozyl&amp;index=10&amp;md5=9e612fdac1a387afd4a2704e07b36099\" rel=\"nofollow noopener\" shape=\"rect\"><i>Reblozyl<\/i><\/a>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$190\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$160\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n19%\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n22%\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.abecma.com%2F&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=Abecma&amp;index=11&amp;md5=fb06a058730ccb4f88bb5bd1aa4fe1ac\" rel=\"nofollow noopener\" shape=\"rect\"><i>Abecma<\/i><\/a>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$107\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$71\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n51%\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n59%\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.zeposia.com%2F&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=Zeposia&amp;index=12&amp;md5=f49cb5c4148fa7407315b3e90736523e\" rel=\"nofollow noopener\" shape=\"rect\"><i>Zeposia<\/i><\/a>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$69\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$40\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n73%\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n83%\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.breyanzi.com%2F&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=Breyanzi&amp;index=13&amp;md5=915909e09b7146247db944dd50520a6b\" rel=\"nofollow noopener\" shape=\"rect\"><i>Breyanzi<\/i><\/a>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$44\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$30\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n47%\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n50%\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.inrebic.com%2F&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=Inrebic&amp;index=14&amp;md5=f201d4224f3b7e4322d2d970a9eb0021\" rel=\"nofollow noopener\" shape=\"rect\"><i>Inrebic<\/i><\/a>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$21\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$22\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n(5)%\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n0%\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.onureg.com%2F&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=Onureg&amp;index=15&amp;md5=0a8918ab8642d813294fc1c7fd415a96\" rel=\"nofollow noopener\" shape=\"rect\"><i>Onureg<\/i><\/a>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$32\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$21\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n52%\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n57%\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.opdualag.com%2F%3Fcid%3Dsem_1631177%26ovl%3Disi%26gclid%3DCj0KCQjwl7qSBhD-ARIsACvV1X0H4h2ZkmfdZxpjkQrvThTXmx-y1_zkOXN8gx-HYdeyfC6GbSxE0JMaAogUEALw_wcB%26gclsrc%3Daw.ds&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=Opdualag&amp;index=16&amp;md5=4ba19636cfab78bbf40cef26512ab045\" rel=\"nofollow noopener\" shape=\"rect\"><i>Opdualag<\/i><\/a>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$84\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n&#8211;\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nN\/A\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nN\/A\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.camzyos.com%2F%3Fcid%3Dsem_1671303%26ovl%3Disi%26gclid%3DCj0KCQjwlK-WBhDjARIsAO2sErT1Z7cdW7f-lfIwVBUepZIRlKZzYOKUWGmPnx7DtB6TmcoTPuFG5z0aAsL6EALw_wcB%26gclsrc%3Daw.ds&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=Camzyos&amp;index=17&amp;md5=e3a93c551a4efe3ba3c192965d878754\" rel=\"nofollow noopener\" shape=\"rect\"><i>Camzyos<\/i><\/a>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$5\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n&#8211;\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nN\/A\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nN\/A\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.sotyktuhcp.com%2F%3Fcid%3Dsem_1921901%26gclid%3DCj0KCQjw7KqZBhCBARIsAI-fTKJgU41nON6P0wfJARMp7LUF9c_hcTKq3SrPrYZUc35_CyFbefmuRnUaAqF9EALw_wcB%26gclsrc%3Daw.ds&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=Sotyktu&amp;index=18&amp;md5=72aed750f9c1a1f625a2cbf7175a27d4\" rel=\"nofollow noopener\" shape=\"rect\"><i>Sotyktu<\/i><\/a>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$1\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n&#8211;\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nN\/A\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nN\/A\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Total New Product Portfolio Revenue<\/b>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<b>$553<\/b>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<b>$344<\/b>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<b>61%<\/b>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<b>66%<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Total In-Line Products and New Product Portfolio Revenue<\/b>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<b>$8,621<\/b>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<b>$8,011<\/b>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<b>8%<\/b>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<b>13%<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth80 bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor0 bwpadl0 bwalignl\" colspan=\"4\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<b>Recent LOE Products<\/b>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.revlimid.com&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=Revlimid&amp;index=19&amp;md5=6c24999c37c9ad0154a5eff45fe555fd\" rel=\"nofollow noopener\" shape=\"rect\"><i>Revlimid<\/i><\/a>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$2,420\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$3,347\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n(28)%\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n(27)%\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.abraxane.com%2F&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=Abraxane&amp;index=20&amp;md5=8a74ccdc2b7cf3cf3d90f0343c23a571\" rel=\"nofollow noopener\" shape=\"rect\"><i>Abraxane<\/i><\/a>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$177\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$266\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n(33)%\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n(32)%\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Total Recent LOE Products Revenue<\/b>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<b>$2,597<\/b>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<b>$3,613<\/b>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<b>(28)%<\/b>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<b>(27)%<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Total Revenue<\/b>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<b>$11,218<\/b>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<b>$11,624<\/b>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<b>(3)%<\/b>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<b>0%<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\n** Includes over-the-counter (OTC) products, royalty revenue and other mature products.\n<\/p>\n<p>\n<b><span class=\"bwuline\">NINE MONTH PRODUCT REVENUE HIGHLIGHTS<\/span><\/b>\n<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwwidth80 bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor0 bwpadl0\" colspan=\"4\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>$ amounts in millions<\/b>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwtopsingle bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>Product<\/b>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<b>Nine-Months<br \/>\n<br \/>Ended<\/b>\n<\/p>\n<p class=\"bwcellpmargin bwalignc\">\n<b>September 30, 2022<\/b>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<b>Nine-Months<br \/>\n<br \/>Ended<\/b>\n<\/p>\n<p class=\"bwcellpmargin bwalignc\">\n<b>September 30, 2021<\/b>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>% Change from<br \/>\n<br \/>Nine-Months<br \/>\n<br \/>Ended September 30, 2021<\/b>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>% Change from<br \/>\n<br \/>Nine-Months<br \/>\n<br \/>Ended September 30, 2021<\/b>\n<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n<b>(Excl. F\/X Impact)<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth80 bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor0 bwpadl0\" colspan=\"4\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>In-Line Products<\/b>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.eliquis.com%2F&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=Eliquis&amp;index=21&amp;md5=8e6b264cb6ac49025ae9fd19499d1d32\" rel=\"nofollow noopener\" shape=\"rect\"><i>Eliquis<\/i><\/a>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$9,101\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$8,091\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n12%\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n17%\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.opdivo.com%2F&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=Opdivo&amp;index=22&amp;md5=c934219cd5d30b6e55000a7acc86e586\" rel=\"nofollow noopener\" shape=\"rect\"><i>Opdivo<\/i><\/a>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$6,033\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$5,535\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n9%\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n13%\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.pomalyst.com&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=Pomalyst%2FImnovid&amp;index=23&amp;md5=933820478762cd8d80b991e332f517a3\" rel=\"nofollow noopener\" shape=\"rect\"><i>Pomalyst<\/i><i>\/Imnovid<\/i><\/a>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$2,620\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$2,478\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n6%\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n9%\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.orencia.com%2F&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=Orencia&amp;index=24&amp;md5=1415f9c1ec0f68726e867bf50ee6e854\" rel=\"nofollow noopener\" shape=\"rect\"><i>Orencia<\/i><\/a>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$2,551\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$2,442\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n4%\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n7%\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sprycel.com%2F&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=Sprycel&amp;index=25&amp;md5=9d1eb1db1ef4e08456916ae3bd3ed2b2\" rel=\"nofollow noopener\" shape=\"rect\"><i>Sprycel<\/i><\/a>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$1,587\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$1,562\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n2%\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n6%\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.yervoy.com%2F&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=Yervoy&amp;index=26&amp;md5=531702d2754d6ba6e368490411001370\" rel=\"nofollow noopener\" shape=\"rect\"><i>Yervoy<\/i><\/a>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$1,563\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$1,481\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n6%\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n10%\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.empliciti.com&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=Empliciti&amp;index=27&amp;md5=acbf9182f9e1ea739ba094d0033028ab\" rel=\"nofollow noopener\" shape=\"rect\"><i>Empliciti<\/i><\/a>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$225\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$253\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n(11)%\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n(6)%\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<i>Mature and Other Products**<\/i>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$1,338\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$1,459\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n(8)%\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n(5)%\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Total In-Line Products Revenue<\/b>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<b>$25,018<\/b>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<b>$23,301<\/b>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<b>7%<\/b>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<b>11%<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth80 bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor0 bwpadl0\" colspan=\"4\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>New Product Portfolio<\/b>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.reblozyl.com%2F&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=Reblozyl&amp;index=28&amp;md5=e881490b9b8acf551d9f797c4dd19ca3\" rel=\"nofollow noopener\" shape=\"rect\"><i>Reblozyl<\/i><\/a>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$518\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$400\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n30%\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n32%\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.abecma.com%2F&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=Abecma&amp;index=29&amp;md5=221f3c7afed2afe239585982562f3750\" rel=\"nofollow noopener\" shape=\"rect\"><i>Abecma<\/i><\/a>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$263\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$95\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n*\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n*\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.zeposia.com%2F&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=Zeposia&amp;index=30&amp;md5=0f7f405b1b66745ebda0170acbe9765f\" rel=\"nofollow noopener\" shape=\"rect\"><i>Zeposia<\/i><\/a>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$171\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$86\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n99%\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n*\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.breyanzi.com%2F&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=Breyanzi&amp;index=31&amp;md5=1818533c89aff416ad67ba223b139746\" rel=\"nofollow noopener\" shape=\"rect\"><i>Breyanzi<\/i><\/a>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$127\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$47\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n*\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n*\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<i><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.inrebic.com%2F&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=Inrebic&amp;index=32&amp;md5=66562fdc9d5b14fd73ea9c0b4f0ad510\" rel=\"nofollow noopener\" shape=\"rect\">Inrebic<\/a><\/i>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$62\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$54\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n15%\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n17%\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.onureg.com%2F&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=Onureg&amp;index=33&amp;md5=f798a922e694d9a8b70d652f52e1c516\" rel=\"nofollow noopener\" shape=\"rect\"><i>Onureg<\/i><\/a>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$87\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$48\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n81%\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n85%\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.opdualag.com%2F%3Fcid%3Dsem_1631177%26ovl%3Disi%26gclid%3DCj0KCQjwl7qSBhD-ARIsACvV1X0H4h2ZkmfdZxpjkQrvThTXmx-y1_zkOXN8gx-HYdeyfC6GbSxE0JMaAogUEALw_wcB%26gclsrc%3Daw.ds&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=Opdualag&amp;index=34&amp;md5=c4dbbebd53f75eb9f68dccfda928e1a6\" rel=\"nofollow noopener\" shape=\"rect\"><i>Opdualag<\/i><\/a>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$148\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n&#8211;\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nN\/A\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nN\/A\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.camzyos.com%2F%3Fcid%3Dsem_1671303%26ovl%3Disi%26gclid%3DCj0KCQjwlK-WBhDjARIsAO2sErT1Z7cdW7f-lfIwVBUepZIRlKZzYOKUWGmPnx7DtB6TmcoTPuFG5z0aAsL6EALw_wcB%26gclsrc%3Daw.ds&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=Camzyos&amp;index=35&amp;md5=1e6ee7524491ca893844bc9aaba05171\" rel=\"nofollow noopener\" shape=\"rect\"><i>Camzyos<\/i><\/a>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$8\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n&#8211;\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nN\/A\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nN\/A\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.sotyktuhcp.com%2F%3Fcid%3Dsem_1921901%26gclid%3DCj0KCQjw7KqZBhCBARIsAI-fTKJgU41nON6P0wfJARMp7LUF9c_hcTKq3SrPrYZUc35_CyFbefmuRnUaAqF9EALw_wcB%26gclsrc%3Daw.ds&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=Sotyktu&amp;index=36&amp;md5=d8b49e1dfc3c7d647e4e7982793bbf14\" rel=\"nofollow noopener\" shape=\"rect\"><i>Sotyktu<\/i><\/a>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$1\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n&#8211;\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nN\/A\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nN\/A\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Total New Product Portfolio Revenue<\/b>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<b>$1,385<\/b>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<b>$730<\/b>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<b>90%<\/b>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<b>94%<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Total In-Line Products and New Product Portfolio Revenue<\/b>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<b>$26,403<\/b>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<b>$24,031<\/b>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<b>10%<\/b>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<b>14%<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth80 bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor0 bwpadl0\" colspan=\"4\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Recent LOE Products<\/b>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.revlimid.com&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=Revlimid&amp;index=37&amp;md5=9c29b699bcc870cb12c7d151107e8d19\" rel=\"nofollow noopener\" shape=\"rect\"><i>Revlimid<\/i><\/a>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$7,718\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$9,493\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n(19)%\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n(18)%\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.abraxane.com%2F&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=Abraxane&amp;index=38&amp;md5=072a7c9bfc2e98c8606353dae5667d61\" rel=\"nofollow noopener\" shape=\"rect\"><i>Abraxane<\/i><\/a>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$632\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n$876\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n(28)%\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n(27)%\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Total Recent LOE Products Revenue<\/b>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<b>$8,350<\/b>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<b>$10,369<\/b>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<b>(19)%<\/b>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<b>(18)%<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwwidth20 bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Total Revenue<\/b>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<b>$34,753<\/b>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<b>$34,400<\/b>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<b>1%<\/b>\n<\/p>\n<\/td>\n<td class=\"bwwidth20 bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignl bwrightsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<b>4%<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\n* In excess of +100%\n<\/p>\n<p>\n** Includes over-the-counter (OTC) products, royalty revenue and other mature products.\n<\/p>\n<p>\n<b><span class=\"bwuline\">REVENUE HIGHLIGHTS<\/span><\/b>\n<\/p>\n<p>\n<b><i>In-Line Products<\/i><\/b>\n<\/p>\n<p>\nRevenues for in-line products in the third quarter were $8.1 billion compared to $7.7 billion in the prior year period, representing an increase of 5% or 10% when adjusted for foreign exchange. In-line products revenue was largely driven by:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\n<i>Eliquis<\/i> revenues grew 10% compared to the prior year period. U.S. revenues were $1.7 billion compared to $1.3 billion in the prior year period, representing an increase of 31% driven primarily by demand growth and favorable gross to net adjustments. International revenues were $926 million compared to $1.1 billion in the prior year period, representing a decrease of 16% driven by foreign exchange impacts and lower average net selling prices. When adjusted for foreign exchange impacts, <i>Eliquis\u2019 <\/i>international revenues declined 2%.\n<\/li>\n<li>\n<i>Opdivo<\/i> revenues increased 7% compared to the prior year period. U.S. revenues were $1.2 billion compared to $1.1 billion in the prior year period, representing an increase of 17% driven by higher demand across multiple indications, including <i>Opdivo <\/i>plus<i> Yervoy-<\/i>based combinations for non-small cell lung cancer, <i>Opdivo <\/i>plus<i> Cabometyx<\/i><sup>\u00ae <\/sup>combination for kidney cancer, and <i>Opdivo<\/i>-based therapies for various gastric, bladder and esophageal cancers, partially offset by declining second-line eligibility across tumors and increased competition. International revenues were $804 million compared to $843 million in the prior year period, representing a decrease of 5% driven by foreign exchange impacts, partially offset by higher demand as a result of launches for additional indications and core indications. When adjusted for foreign exchange impacts, <i>Opdivo\u2019s<\/i> international revenues increased 8%.\n<\/li>\n<\/ul>\n<p>\n<b><i>New Product Portfolio<\/i><\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nNew product portfolio revenues grew to $553 million compared to $344 million in the prior year period, representing growth of 61% driven by the launch of <i>Opdualag<\/i><i> <\/i>and higher demand for<i> Abecma <\/i>and <i>Reblozyl<\/i>. Excluding foreign exchange, new product portfolio revenues grew 66%.\n<\/li>\n<\/ul>\n<p>\n<b><i>Recent LOE Products<\/i><\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\n<i>Revlimid<\/i> revenues declined by 28% compared to the prior year period. U.S. revenues decreased 6% to $2.2 billion as compared to the prior year period primarily driven by lower demand as a result of generic erosion. International revenues were $250 million compared to $1.0 billion in the prior year period, representing a decrease of 76% driven by lower demand as a result of generic erosion and to a lesser extent, foreign exchange impacts.\n<\/li>\n<\/ul>\n<p>\n<b><span class=\"bwuline\">PRODUCT AND PIPELINE UPDATE<\/span><\/b>\n<\/p>\n<p>\n<b>Cardiovascular<\/b>\n<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor0 bwpadl0 bwwidth7\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Category<\/b>\n<\/p>\n<\/td>\n<td class=\"bwtopsingle bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwwidth9\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Asset<\/b>\n<\/p>\n<\/td>\n<td class=\"bwtopsingle bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwwidth84\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Milestone<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth7\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Regulatory<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth9\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<i>Camzyos<sup>\u00ae<\/sup><\/i>\n<\/p>\n<p class=\"bwcellpmargin\">\n(mavacamten)\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth84\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nThe U.S. Food and Drug Administration (FDA) has <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fnews.bms.com%2Fnews%2Fcorporate-financial%2F2022%2FU.S.-Food-and-Drug-Administration-FDA-Accepts-Supplemental-New-Drug-Application-for-CAMZYOS-mavacamten-in-Symptomatic-Obstructive-Hypertrophic-Cardiomyopathy-to-Reduce-the-Need-for-Septal-Reduction-Therapy%2Fdefault.aspx&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=accepted&amp;index=39&amp;md5=7f1874e0aac1e46e91ba148d04ad8a34\" rel=\"nofollow noopener\" shape=\"rect\">accepted<\/a> our supplemental new drug application for <i>Camzyos<\/i> for an expanded indication for the treatment of adults with symptomatic New York Heart Association class II-III obstructive hypertrophic cardiomyopathy to improve functional capacity, improve symptoms and reduce the need for septal reduction therapy. The FDA assigned a Prescription Drug User Fee Act goal date of June 16, 2023.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth7\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Clinical &amp; Research<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth9\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nMilvexian\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth84\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fnews.bms.com%2Fnews%2Fdetails%2F2022%2FLate-Breaking-Results-From-Phase-2-AXIOMATIC-SSP-Study-of-Milvexian-an-Investigational-Oral-Factor-XIa-Inhibitor-Show-Favorable-Antithrombotic-Profile-in-Combination-With-Dual-Antiplatelet-Therapy%2Fdefault.aspx&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=Phase+2+AXIOMATIC-SSP&amp;index=40&amp;md5=b1e1e617905eba157a47506a26918583\" rel=\"nofollow noopener\" shape=\"rect\">Phase 2 AXIOMATIC-SSP<\/a> trial showed that milvexian had an approximate 30% relative risk reduction in recurrent symptomatic ischemic strokes (accepted regulatory endpoint) and favorable safety profile in three arms compared to placebo when used in combination with background dual antiplatelet therapy in patients with an acute non-cardioembolic ischemic stroke or transient ischemic attack. The primary objective of this trial was to detect a dose response for the composite endpoint of symptomatic ischemic stroke + MRI detected covert brain infarction across a 16-fold dose range; a dose response was not observed for the composite endpoint. The trial was conducted by The Bristol Myers Squibb-Janssen Collaboration.\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\n<b>Oncology<\/b>\n<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor0 bwpadl0 bwwidth7\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Category<\/b>\n<\/p>\n<\/td>\n<td class=\"bwtopsingle bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwwidth9\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Asset<\/b>\n<\/p>\n<\/td>\n<td class=\"bwtopsingle bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwwidth84\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Milestone<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth7\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Regulatory<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth9\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<i>Opdualag<sup>TM<\/sup><\/i>\n<\/p>\n<p class=\"bwcellpmargin\">\n(nivolumab and relatlimab-rmbw)\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth84\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nThe European Commission (EC) <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fnews.bms.com%2Fnews%2Fcorporate-financial%2F2022%2FBristol-Myers-Squibb-Receives-European-Commission-Approval-for-LAG-3-Blocking-Antibody-Combination-Opdualag-nivolumab-and-relatlimab-for-the-Treatment-of-Unresectable-or-Metastatic-Melanoma-with-Tumor-Cell-PD-L1-Expression--1%2Fdefault.aspx&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=approved&amp;index=41&amp;md5=1869b4da508817cee39716eee733dfd4\" rel=\"nofollow noopener\" shape=\"rect\">approved<\/a> the fixed-dose combination of <i>Opdualag<\/i> for the first-line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumor cell PD-L1 expression &lt; 1%. The EC\u2019s decision is based upon an exploratory analysis of results from the Phase 2\/3 RELATIVITY-047 trial.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth7\" colspan=\"1\" rowspan=\"2\">\n<p class=\"bwcellpmargin\">\n<b>Clinical &amp; Research<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth9\" colspan=\"1\" rowspan=\"2\">\n<p class=\"bwcellpmargin\">\n<i>Opdivo<sup>\u00ae<\/sup><\/i>\n<\/p>\n<p class=\"bwcellpmargin\">\n(nivolumab)\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth84\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nPhase 3 <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fnews.bms.com%2Fnews%2Fcorporate-financial%2F2022%2FBristol-Myers-Squibb-Announces-Adjuvant-Treatment-with-Opdivo-nivolumab-Demonstrated-Statistically-Significant-and-Clinically-Meaningful-Improvement-in-Recurrence-Free-Survival-RFS-in-Patients-with-Stage-IIBC-Melanoma-in-the-CheckMate--76K-Trial%2Fdefault.aspx&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=CheckMate+-76K&amp;index=42&amp;md5=5cc3de5843e31a7965459b4d4a578cc1\" rel=\"nofollow noopener\" shape=\"rect\">CheckMate -76K<\/a> trial evaluating <i>Opdivo<\/i> as a single agent in the adjuvant setting in patients with completely resected stage IIB\/C melanoma met its primary endpoint and demonstrated a statistically significant and clinically meaningful benefit in recurrence-free survival versus placebo at a pre-specified interim analysis.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth84\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nPart A of the <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fnews.bms.com%2Fnews%2Fcorporate-financial%2F2022%2FBristol-Myers-Squibb-Provides-Update-on-CheckMate--914-Trial-Evaluating-Opdivo-nivolumab-Plus-Yervoy-ipilimumab-as-Adjuvant-Treatment-of-Localized-Renal-Cell-Carcinoma%2Fdefault.aspx&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=Phase+3+CheckMate+%26%238211%3B914&amp;index=43&amp;md5=68c5e2ec1c7917672982ef6dfc7ae215\" rel=\"nofollow noopener\" shape=\"rect\">Phase 3 CheckMate \u2013914<\/a> trial, evaluating <i>Opdivo<\/i> plus <i>Yervoy<\/i> as an adjuvant treatment for patients with localized renal cell carcinoma who have undergone full or partial removal of the kidney and who are at moderate or high risk of relapse, did not meet the primary endpoint of disease-free survival as assessed by Blinded Independent Central Review. The safety profile was consistent with previously reported studies of the <i>Opdivo<\/i> plus <i>Yervoy<\/i> combination in solid tumors.\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\n<b>Hematology<\/b>\n<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor0 bwpadl0 bwwidth7\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Category<\/b>\n<\/p>\n<\/td>\n<td class=\"bwtopsingle bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwwidth9\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Asset<\/b>\n<\/p>\n<\/td>\n<td class=\"bwtopsingle bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwwidth84\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Milestone<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth7\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Clinical &amp; Research<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth9\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<i>Abecma<sup>\u00ae<\/sup><\/i>\n<\/p>\n<p class=\"bwcellpmargin\">\n(idecabtagene vicleucel)\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth84\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nPositive topline results from the Phase 3 <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fnews.bms.com%2Fnews%2Fcorporate-financial%2F2022%2FBristol-Myers-Squibb-and-2seventy-bio-Announce-Topline-Results-from-KarMMa-3-Trial-Showing-Abecma-idecabtagene-vicleucel-Significantly-Improves-Progression-Free-Survival-Versus-Standard-Regimens-in-Relapsed-and-Refractory-Multiple-Myeloma%2Fdefault.aspx&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=KarMMa-3&amp;index=44&amp;md5=594c7f07990150d4e0895eefa6e49a96\" rel=\"nofollow noopener\" shape=\"rect\">KarMMa-3<\/a> trial showed treatment with <i>Abecma<\/i> compared to standard combination regimens in adults with relapsed and refractory multiple myeloma after two to four prior lines of therapy and refractory to the last regimen met its primary endpoint of demonstrating a statistically significant improvement in progression-free survival. Treatment with <i>Abecma<\/i> also showed an improvement in the key secondary endpoint of overall response rate compared to standard regimens. The trial was conducted with 2seventy bio (NASDAQ: TSVT).\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\n<b>Immunology<\/b>\n<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor0 bwpadl0 bwwidth7\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Category<\/b>\n<\/p>\n<\/td>\n<td class=\"bwtopsingle bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwwidth7\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Asset<\/b>\n<\/p>\n<\/td>\n<td class=\"bwtopsingle bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwwidth86\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Milestone<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth7\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Regulatory<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth7\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<i>Sotyktu<sup>TM<br \/>\n<br \/><\/sup><\/i>(deucravacitinib)\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth86\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nThe FDA <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fnews.bms.com%2Fnews%2Fcorporate-financial%2F2022%2FU.S.-Food-and-Drug-Administration-Approves-Sotyktu-deucravacitinib-Oral-Treatment-for-Adults-with-Moderate-to-Severe-Plaque-Psoriasis%2Fdefault.aspx&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=approved&amp;index=45&amp;md5=723302bf3184b836be4bb62197e08666\" rel=\"nofollow noopener\" shape=\"rect\">approved<\/a> <i>Sotyktu,<\/i> a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.\n<\/p>\n<p class=\"bwcellpmargin\">\nIn addition, Japan\u2019s Ministry of Health, Labour and Welfare approved <i>Sotyktu<\/i> for the treatment of patients with plaque psoriasis, generalized pustular psoriasis, or erythrodermic psoriasis, who have had an inadequate response to conventional therapies. The approvals are based on results from the pivotal Phase 3 POETYK PSO-1 and POETYK PSO-2 clinical trials.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwleftsingle bwrightsingle bwpadl0 bwsinglebottom bwwidth7\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Clinical &amp; Research<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth7\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<i>Sotyktu<\/i>\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth86\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nTwo-year results from the <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fnews.bms.com%2Fnews%2Fcorporate-financial%2F2022%2FBristol-Myers-Squibb-Announces-New-Sotyktu-deucravacitinib-Long-Term-Data-Showing-Clinical-Efficacy-Maintained-for-Up-to-Two-Years-with-Continuous-Treatment-in-Moderate-to-Severe-Plaque-Psoriasis%2Fdefault.aspx&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=POETYK+PSO+long-term+extension&amp;index=46&amp;md5=6bfcf1c271d54508e7d65c23f2f0858e\" rel=\"nofollow noopener\" shape=\"rect\">POETYK PSO long-term extension<\/a> trial demonstrated that clinical efficacy was maintained with continuous <i>Sotyktu <\/i>treatment in adult patients with moderate-to-severe plaque psoriasis.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwleftsingle bwrightsingle bwpadl0 bwsinglebottom bwwidth7\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwrightsingle bwpadl0 bwsinglebottom bwwidth7\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<i>Zeposia<\/i><sup>\u00ae<\/sup>\n<\/p>\n<p class=\"bwcellpmargin\">\n(ozanimod)\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth86\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nNew <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fnews.bms.com%2Fnews%2Fcorporate-financial%2F2022%2FNew-Data-Presented-at-the-American-College-of-Gastroenterology-Annual-Scientific-Meeting-Demonstrate-Continuous-Zeposia-ozanimod-Treatment-Prevents-Disease-Relapse-Over-One-Year-in-86.1-of-Patients-Who-Respond-at-the-End-of-the-Induction-Period%2Fdefault.aspx&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=post+hoc+analyses&amp;index=47&amp;md5=1e4fdba2bb75b8add8bf1e4f211213ee\" rel=\"nofollow noopener\" shape=\"rect\">post hoc analyses<\/a> from the Phase 3 True North trial evaluating duration of response following continuous <i>Zeposia<\/i> treatment for up to one year and following treatment interruption in patients with moderately to severely active ulcerative colitis showed that <i>Zeposia <\/i>prevents disease relapse over one year of continuous treatment and maintains disease control even in the event of temporary interruption.\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\n<b><span class=\"bwuline\">Business Development<\/span><\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nIn August, the company announced that it had completed its acquisition of Turning Point in an all-cash transaction. Through the transaction, the company gained repotrectinib, a next-generation, potential best-in-class tyrosine kinase inhibitor targeting the ROS1 and NTRK oncogenic drivers of non-small cell lung cancer (NSCLC) and other advanced solid tumors. (<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fnews.bms.com%2Fnews%2Fcorporate-financial%2F2022%2FBristol-Myers-Squibb-Completes-Acquisition-of-Turning-Point-Therapeutics-Expanding-Precision-Oncology-Portfolio%2Fdefault.aspx&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=link&amp;index=48&amp;md5=98257f1a57beda12abc6105108b79ba7\" rel=\"nofollow noopener\" shape=\"rect\">link<\/a>)\n<\/li>\n<\/ul>\n<p>\n<b><span class=\"bwuline\">Environmental, Social &amp; Governance (ESG)<\/span><\/b>\n<\/p>\n<p>\nAs a leading biopharma company, we understand our responsibility extends well beyond the discovery, development, and delivery of innovative medicines. Our evolving Environmental, Social, and Governance (ESG) strategy builds on a legacy of comprehensive and global sustainability efforts. To learn more about our priorities and goals, please visit our latest <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.corporatereport.com%2Fbms%2F2020%2Fesg%2F&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=ESG+report&amp;index=49&amp;md5=76f99e0a4e8496f96c0450d49cea3ec0\" rel=\"nofollow noopener\" shape=\"rect\">ESG report<\/a>.\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nIn September, the company issued our 2021 Global Inclusion and Diversity Report which outlines our strategy and the progress we have made toward our 2025 Inclusion &amp; Diversity and Health Equity Commitments, among others. To learn more, please visit our latest <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.bms.com%2Fabout-us%2Fglobal-diversity-and-inclusion%2Fdiversity-and-inclusion-report%2F2021-cido-letter.html&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=Global+Inclusion+%26amp%3B+Diversity+Report&amp;index=50&amp;md5=98bfbcffe39a27368df58b190da1c8c6\" rel=\"nofollow noopener\" shape=\"rect\">Global Inclusion &amp; Diversity Report<\/a>.\n<\/li>\n<\/ul>\n<p>\n<b><span class=\"bwuline\">Financial Guidance<\/span><\/b>\n<\/p>\n<p>\nBristol Myers Squibb is adjusting its 2022 GAAP line-item guidance as follows:\n<\/p>\n<p>\nAdjusting GAAP EPS guidance primarily due to the acquisition of Turning Point and reaffirming non-GAAP EPS guidance.\n<\/p>\n<p>\nKey 2022 GAAP and non-GAAP line-item guidance assumptions are:\n<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwtopsingle\" colspan=\"1\" rowspan=\"2\">\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0\" colspan=\"2\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>U.S. GAAP<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0\" colspan=\"2\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>Non-GAAP<\/b>\n<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>July<\/b>\n<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n<b>(Prior)<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>October<\/b>\n<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n<b>(Revised)<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>July<\/b>\n<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n<b>(Prior)<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>October<\/b>\n<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n<b>(Revised)<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Total Sales<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n~$46.0 billion\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nNo change\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n~$46.0 billion\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nNo change\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Recent LOE Products<sup>1<\/sup><\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n~$10.0 billion or\n<\/p>\n<p class=\"bwalignc bwcellpmargin\">\ndouble-digit decline\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nNo change\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n~$10.0 billion or\n<\/p>\n<p class=\"bwalignc bwcellpmargin\">\ndouble-digit decline\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nNo change\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b><i>Revlimid<\/i><\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n$9.0-$9.5 billion\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nNo change\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n$9.0-$9.5 billion\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nNo change\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>In-line Products &amp; New Product Portfolio<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n~$36.0 billion or\n<\/p>\n<p class=\"bwalignc bwcellpmargin\">\nLow double-digit increase\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nNo change\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n~$36.0 billion or\n<\/p>\n<p class=\"bwalignc bwcellpmargin\">\nLow double-digit increase\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nNo change\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Gross Margin %<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n~78%\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nNo change\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n~79%\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nNo change\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Operating Expenses<sup>2<\/sup><\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nMid single-digit decline\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nNo change\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nLow single-digit decline\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nNo change\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Tax Rate<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n~23%\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n~24%\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n~16.5%\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nNo change\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Diluted EPS<sup>3<\/sup><\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n$2.71-$3.01\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n$2.54-$2.84\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n$7.44 &#8211; $.7.74\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nNo change\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\n<sup>1 <\/sup>Key LOE Products = Revlimid and Abraxane\n<\/p>\n<p>\n<sup>2<\/sup> Operating Expenses = MS&amp;A and R&amp;D, excluding Acquired IPRD and Amortization of acquired intangible assets\n<\/p>\n<p>\n<sup>3 <\/sup>July guidance includes YTD net impact of ($0.24) from Acquired IPRD and licensing income; October guidance includes net impact of ($0.22) from Acquired IPRD and licensing income\n<\/p>\n<p>\nThe 2022 financial guidance excludes the impact of any potential future strategic acquisitions and divestitures, and any specified items that have not yet been identified and quantified and impact of future Acquired IPRD charges. To the extent we have quantified the impact of significant R&amp;D charges or other income resulting from upfront or contingent milestone payments in connection with asset acquisitions or licensing of third-party intellectual property rights, we may update this information from time to time on our website, <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bms.com&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=www.bms.com&amp;index=51&amp;md5=d6823a2f6d8145c92841abb751f58caa\" rel=\"nofollow noopener\" shape=\"rect\">www.bms.com<\/a>, in the \u201cInvestors\u201d section. GAAP and non-GAAP guidance assume current exchange rates. The 2022 non-GAAP EPS guidance is further explained under \u201cUse of Non-GAAP Financial Information.\u201d The financial guidance is subject to risks and uncertainties applicable to all forward-looking statements as described elsewhere in this press release.\n<\/p>\n<p>\n<b><span class=\"bwuline\">Conference Call Information<\/span><\/b>\n<\/p>\n<p>\nBristol Myers Squibb will host a conference call tomorrow, Wednesday, October 26, 2022 at 8 a.m. ET during which company executives will review the quarterly financial results and address inquiries from investors and analysts.\n<\/p>\n<p>\nInvestors and the general public are invited to listen to a live webcast of the call at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Finvestor.bms.com&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=http%3A%2F%2Finvestor.bms.com&amp;index=52&amp;md5=72f371d1ea9269827af8661fc106416c\" rel=\"nofollow noopener\" shape=\"rect\">http:\/\/investor.bms.com<\/a>. Investors and the public can also access the live webcast by dialing in the U.S. toll free 888-330-2388 or international +1 240-789-2707, confirmation code: 24168. Dial-in participants can register for the conference call <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fconferencingportals.com%2Fevent%2FiwhNSMuQ&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=here&amp;index=53&amp;md5=3ad718fd1ecfc3362a18c39dcc6a8941\" rel=\"nofollow noopener\" shape=\"rect\">here<\/a> and once registration is complete, will not require operator assistance to connect. Materials related to the call will be available at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Finvestor.bms.com&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=http%3A%2F%2Finvestor.bms.com&amp;index=54&amp;md5=f77b3f6e9aa5c6751ac27cf822758f90\" rel=\"nofollow noopener\" shape=\"rect\">http:\/\/investor.bms.com<\/a> prior to the start of the conference call.\n<\/p>\n<p>\nA replay of the webcast will be available on <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Finvestor.bms.com&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=http%3A%2F%2Finvestor.bms.com&amp;index=55&amp;md5=0fb00350bcfda03ef103db38876d8d73\" rel=\"nofollow noopener\" shape=\"rect\">http:\/\/investor.bms.com<\/a> approximately three hours after the conference call concludes. A replay of the conference call will be available beginning at 11:30 a.m. ET on October 26 through 11:30 a.m. ET on November 9, 2022, by dialing in the U.S. toll free 800-770-2030 or international +1 647-362-9199, confirmation code: 24168.\n<\/p>\n<p>\n<b><span class=\"bwuline\">About Bristol Myers Squibb<\/span><\/b>\n<\/p>\n<p>\nBristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fbristol-myers-squibb%2F&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=56&amp;md5=7e6d057c796530061d2ed9bc3ed859b7\" rel=\"nofollow noopener\" shape=\"rect\">LinkedIn<\/a>, <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Fbmsnews&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=Twitter&amp;index=57&amp;md5=80a0a457bd5f4420d41f111e63a1759a\" rel=\"nofollow noopener\" shape=\"rect\">Twitter<\/a>, <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.youtube.com%2Fbristolmyerssquibb&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=YouTube&amp;index=58&amp;md5=0f72b0618223ef4415aa533354151cd0\" rel=\"nofollow noopener\" shape=\"rect\">YouTube<\/a>, <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FBristolMyersSquibb%2F&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=Facebook&amp;index=59&amp;md5=8267f8eef43bae49f859a675379cf362\" rel=\"nofollow noopener\" shape=\"rect\">Facebook<\/a>, and <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fbristolmyerssquibb%2F&amp;esheet=52952606&amp;newsitemid=20221026005143&amp;lan=en-US&amp;anchor=Instagram&amp;index=60&amp;md5=723fe1a8db52f6f95792ec21c84f466c\" rel=\"nofollow noopener\" shape=\"rect\">Instagram<\/a>.\n<\/p>\n<p>\n<b><span class=\"bwuline\">Use of Non-GAAP Financial Information<\/span><\/b>\n<\/p>\n<p>\nIn discussing financial results and guidance, the company refers to financial measures that are not in accordance with U.S. Generally Accepted Accounting Principles (GAAP). The non-GAAP financial measures are provided as supplemental information to the financial measures presented in this press release that are calculated and presented in accordance with GAAP and are presented because management has evaluated the company\u2019s financial results both including and excluding the adjusted items or the effects of foreign currency translation, as applicable, and believes that the non-GAAP financial measures presented portray the results of the company\u2019s baseline performance, supplement or enhance management, analysts and investors overall understanding of the company\u2019s underlying financial performance and trends and facilitate comparisons among current, past and future periods. In addition, non-GAAP gross margin, which is gross profit excluding certain specified items, as a percentage of revenues, non-GAAP operating expenses, which is marketing, selling and administrative and research and development expenses excluding certain specified items, non-GAAP marketing, selling and administrative expenses, which is marketing, selling and administrative expense excluding certain specified items, and non-GAAP research and development expenses, which is research and development expenses excluding certain specified items, are relevant and useful for investors because they allow investors to view performance in a manner similar to the method used by our management and make it easier for investors, analysts and peers to compare our operating performance to other companies in our industry and to compare our year-over-year results.\n<\/p>\n<p>\nThis earnings release and the accompanying tables also provide certain revenues and expenses as well as non-GAAP measures excluding the impact of foreign exchange. We calculate foreign exchange impacts by converting our current-period local currency financial results using the prior period average currency rates and comparing these adjusted amounts to our current-period results.<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nMedia: <a target=\"_blank\" href=\"m&#97;&#105;&#108;&#x74;&#x6f;&#x3a;me&#100;&#105;&#x61;&#x40;&#x62;&#x6d;s&#46;&#99;&#111;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#109;e&#x64;i&#x61;&#64;&#x62;&#109;&#x73;&#46;&#x63;&#111;m<\/a><br \/>Investor Relations: <a target=\"_blank\" href=\"&#109;&#x61;i&#108;&#x74;o&#x3a;&#x69;&#110;&#x76;e&#115;&#x74;o&#114;&#x2e;&#114;&#x65;l&#97;&#x74;i&#111;&#x6e;&#115;&#x40;&#x62;&#109;&#x73;&#46;&#99;&#x6f;m\" rel=\"nofollow noopener\" shape=\"rect\">&#x69;&#110;v&#x65;&#115;&#116;&#x6f;&#x72;&#46;r&#x65;&#108;a&#x74;&#x69;&#111;n&#x73;&#64;b&#x6d;&#x73;&#46;c&#x6f;&#109;<\/a>\n<\/p>\n<p>\n\u00a0\n<\/p>\n<p> <a href=\"http:\/\/www.businesswire.com\/news\/home\/20221026005143\/en\/Bristol-Myers-Squibb-Reports-Third-Quarter-Financial-Results-for-2022%C2%A0\/?feedref=Zd8jjkgYuzBwDixoAdXmJgT1albrG1Eq4mAeVP392103_ypKzv-7ah0oHKWbnuHnevRMp3sIgu8q3wq1OF24lT93qbEzrwa15HGbLqMObxZM7XiMhduiSeKMTNDLRqI_doMC3CVAuyHo5cJ7XfDuvA==\"> Read full story here <\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Reports Third Quarter Revenues of $11.2 Billion Delivers Strong Revenue Growth of 8% from In-Line Products and New Product Portfolio; or 13% When Adjusted for Foreign Exchange Posts Third Quarter Earnings Per Share of $0.75 and Non-GAAP EPS of $1.99; Includes Net Increase of $0.02 Per Share for GAAP and Non-GAAP EPS Due to Acquired &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/bristol-myers-squibb-reports-third-quarter-financial-results-for-2022\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-50071","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Bristol Myers Squibb Reports Third Quarter Financial Results for 2022\u00a0 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/bristol-myers-squibb-reports-third-quarter-financial-results-for-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bristol Myers Squibb Reports Third Quarter Financial Results for 2022\u00a0 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Reports Third Quarter Revenues of $11.2 Billion Delivers Strong Revenue Growth of 8% from In-Line Products and New Product Portfolio; or 13% When Adjusted for Foreign Exchange Posts Third Quarter Earnings Per Share of $0.75 and Non-GAAP EPS of $1.99; Includes Net Increase of $0.02 Per Share for GAAP and Non-GAAP EPS Due to Acquired ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/bristol-myers-squibb-reports-third-quarter-financial-results-for-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-26T00:01:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221026005143\/en\/785876\/21\/BMS_LOGO.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"16 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bristol-myers-squibb-reports-third-quarter-financial-results-for-2022\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bristol-myers-squibb-reports-third-quarter-financial-results-for-2022\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Bristol Myers Squibb Reports Third Quarter Financial Results for 2022\u00a0\",\"datePublished\":\"2022-10-26T00:01:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bristol-myers-squibb-reports-third-quarter-financial-results-for-2022\\\/\"},\"wordCount\":3246,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bristol-myers-squibb-reports-third-quarter-financial-results-for-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221026005143\\\/en\\\/785876\\\/21\\\/BMS_LOGO.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bristol-myers-squibb-reports-third-quarter-financial-results-for-2022\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bristol-myers-squibb-reports-third-quarter-financial-results-for-2022\\\/\",\"name\":\"Bristol Myers Squibb Reports Third Quarter Financial Results for 2022\u00a0 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bristol-myers-squibb-reports-third-quarter-financial-results-for-2022\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bristol-myers-squibb-reports-third-quarter-financial-results-for-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221026005143\\\/en\\\/785876\\\/21\\\/BMS_LOGO.jpg\",\"datePublished\":\"2022-10-26T00:01:41+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bristol-myers-squibb-reports-third-quarter-financial-results-for-2022\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bristol-myers-squibb-reports-third-quarter-financial-results-for-2022\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bristol-myers-squibb-reports-third-quarter-financial-results-for-2022\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221026005143\\\/en\\\/785876\\\/21\\\/BMS_LOGO.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221026005143\\\/en\\\/785876\\\/21\\\/BMS_LOGO.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bristol-myers-squibb-reports-third-quarter-financial-results-for-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bristol Myers Squibb Reports Third Quarter Financial Results for 2022\u00a0\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Bristol Myers Squibb Reports Third Quarter Financial Results for 2022\u00a0 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/bristol-myers-squibb-reports-third-quarter-financial-results-for-2022\/","og_locale":"en_US","og_type":"article","og_title":"Bristol Myers Squibb Reports Third Quarter Financial Results for 2022\u00a0 - Pharma Trend","og_description":"Reports Third Quarter Revenues of $11.2 Billion Delivers Strong Revenue Growth of 8% from In-Line Products and New Product Portfolio; or 13% When Adjusted for Foreign Exchange Posts Third Quarter Earnings Per Share of $0.75 and Non-GAAP EPS of $1.99; Includes Net Increase of $0.02 Per Share for GAAP and Non-GAAP EPS Due to Acquired ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/bristol-myers-squibb-reports-third-quarter-financial-results-for-2022\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-26T00:01:41+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221026005143\/en\/785876\/21\/BMS_LOGO.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"16 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/bristol-myers-squibb-reports-third-quarter-financial-results-for-2022\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/bristol-myers-squibb-reports-third-quarter-financial-results-for-2022\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Bristol Myers Squibb Reports Third Quarter Financial Results for 2022\u00a0","datePublished":"2022-10-26T00:01:41+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/bristol-myers-squibb-reports-third-quarter-financial-results-for-2022\/"},"wordCount":3246,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/bristol-myers-squibb-reports-third-quarter-financial-results-for-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221026005143\/en\/785876\/21\/BMS_LOGO.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/bristol-myers-squibb-reports-third-quarter-financial-results-for-2022\/","url":"https:\/\/pharma-trend.com\/en\/bristol-myers-squibb-reports-third-quarter-financial-results-for-2022\/","name":"Bristol Myers Squibb Reports Third Quarter Financial Results for 2022\u00a0 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/bristol-myers-squibb-reports-third-quarter-financial-results-for-2022\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/bristol-myers-squibb-reports-third-quarter-financial-results-for-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221026005143\/en\/785876\/21\/BMS_LOGO.jpg","datePublished":"2022-10-26T00:01:41+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/bristol-myers-squibb-reports-third-quarter-financial-results-for-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/bristol-myers-squibb-reports-third-quarter-financial-results-for-2022\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/bristol-myers-squibb-reports-third-quarter-financial-results-for-2022\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221026005143\/en\/785876\/21\/BMS_LOGO.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221026005143\/en\/785876\/21\/BMS_LOGO.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/bristol-myers-squibb-reports-third-quarter-financial-results-for-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Bristol Myers Squibb Reports Third Quarter Financial Results for 2022\u00a0"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50071","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=50071"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50071\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=50071"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=50071"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=50071"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}